# Monitoring adherence and patient-reported outcomes during subcutaneous immunotherapy for house dust mites with the AllergyVax app/web platform

## TL;DR

A digital platform called AllergyVax was used to monitor adherence and outcomes in patients undergoing subcutaneous immunotherapy for house dust mites.

## Contribution

The study introduces a digital platform for real-time monitoring of adherence and outcomes in subcutaneous immunotherapy.

## Key findings

- 84.3% of patients adhered to treatment over 12 months.
- The platform improved patient engagement and adherence without significant differences between subgroups.
- No statistically significant differences were found between patient subgroups in adherence.

## Abstract

Adherence to treatment and outcome monitoring remain major challenges in allergen immunotherapy.

This study evaluated a digital strategy for monitoring adherence and clinical outcomes of subcutaneous immunotherapy (SCIT) through the AllergyVax mobile and web platform.

This prospective observational study followed 83 patients receiving SCIT through the AllergyVax digital platform for 12 months. Patient-reported outcomes were assessed with the Rhinitis Control Assessment Test and the Asthma Control Test at baseline and predefined follow-up intervals. Both adherence and clinical outcomes were analyzed longitudinally in the same patient group. Methodologic limitations include absence of a control group and relatively short follow-up.

The assessment of adherence to SCIT revealed that 84.3% of patients adhered to treatment, 7.2% were recovered adherent patients, and 8.4% dropped out after 12 months of treatment. We compared subgroups by analyzing adherence in patients with rhinitis alone versus those with rhinitis and asthma, as well as between male and female patients. None of the comparisons revealed statistically significant differences between the groups.

The digital platform facilitates SCIT management by improving adherence and strengthening patient engagement.